TWi Biotechnology
Manufacturing · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8f no.41 ln.221 Kang Chien Rd, Taipei, 1...Phone Number
+886 226571788Website
www.twibiotech.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About TWi Biotechnology
TWi Biotechnology, Inc. is a Taiwan-based company focused on developing new drugs for rare diseases, particularly those that currently lack effective treatments. The company specializes in drug repositioning, utilizing existing clinical drugs to meet the medical needs of patients with severe and untreatable rare diseases. Their core values emphasize improving patient quality of life through innovative and safe drug solutions. TWi Biotechnology aims to provide effective therapies to patients worldwide who are in urgent need.Explore more
TWi Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TWi Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at TWi Biotechnology
TWi Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if TWi Biotechnology had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TWi Biotechnology is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if TWi Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once TWi Biotechnology has new funding data
Earning: See what the market has to say on TWi Biotechnology recently announced quarterly report
Product Launch: Get notified when TWi Biotechnology launches new products
Recommended Actions
Reach out to Masked Content who joined TWi Biotechnology as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
TWi Biotechnology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TWi Biotechnology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TWi Biotechnology.
TWi Biotechnology Tech Stack
A closer look at the technologies used by TWi Biotechnology
See more technologies
TWi Biotechnology News & Media
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs for unmet medical needs, is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating phyWinhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
SHANGHAI and TAIPEI, Jan. 6, 2021 /PRNewswire/ -- Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland...TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA
TWi Biotechnology (TWiB) announced that they have received Clinical Trial Application (CTA) approval from the Health Canada to conduct a Phase 1 clinical trial with AC-1101 gel. AC-1101 is a topical JAK inhibitor for the potential treatment of patients with vitiligo. Currently, there are no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved drug therapies for the treatment of vitiligo.TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of-Concept Study of AC-203 for Treatment of Epidermolysis Bullosa
TAIPEI, Taiwan, Jan. 22, 2019 /PRNewswire/ -- TWi Biotechnology Inc. (TWiB), a clinical stage biopharmaceutical company focused on development of novel products for rare diseases associated with chronic inflammation, announced today that it has completed patient enrollment in its Phase 2...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TWi Biotechnology
Sign Up For FreeTo access detailed company insights
TWi Biotechnology, Inc. is a Taiwan-based company focused on developing new drugs for rare diseases, particularly those that currently lack effective treatments. The company specializes in drug repositioning, utilizing existing clinical drugs to meet the medical needs of patients with severe and untreatable rare diseases. Their core values emphasiz... Read More
